<DOC>
	<DOCNO>NCT02456402</DOCNO>
	<brief_summary>This randomized trial ass efficacy Drug Coated Balloon ( DCB ) compare Bare Metal Stent ( BMS ) use Fractional Flow Reserve ( FFR ) guidance de novo coronary artery lesion patient unable tolerate dual antiplatelet therapy high risk bleeding . Patients randomize balloon angioplasty receive either DCB BMS . Endpoints late luminal loss 9 month , major adverse cardiac event include arterial thrombosis 1 , 9 12 month .</brief_summary>
	<brief_title>Drug Coated Balloon Compared Bare Metal Stent de Novo Coronary Artery Lesions</brief_title>
	<detailed_description>Although use drug-eluting stent ( DES ) reduce in-stent restenosis compare bare metal stent ( BMS ) decrease incidence adverse clinical event ( 1-2 ) , DES therapy limit delayed arterial healing , late acquire malapposition neo-atherosclerosis lead increase risk late stent thrombosis late restenosis ( 3-4 ) . Conceptually , permanent stent inhibits advantageous vascular remodel durable polymer provokes excessive inflammation ( 5 ) . Non-stent base local drug delivery use paclitaxel-coated balloon emerge new clinical treatment alternative maintain anti-proliferative property DES ( 6 ) . There limited data efficacy Drug Coated Balloon ( DCB ) treatment de novo coronary lesion compare BMS . To avoid risk abrupt closure target lesion balloon angioplasty , reliable predictor coronary flow necessary especially de novo lesion major coronary artery . Therefore , use fractional flow reserve ( FFR ) angioplasty good indicator immediate functional improvement reduce restenosis ( 7 ) , aim study assess efficacy DCB treatment compare BMS patient de novo coronary artery lesion . Patients de novo coronary artery lesion &gt; 50 % stenosis single vessel high risk bleed inability tolerate dual antiplatelet therapy ( DAPT ) include trial . Patients undergo balloon angioplasty FFR post balloon angioplasty &gt; 0.80 , randomize receive either DCB BMS . Patients receive Quantitative Coronary Angiography ( QCA ) analysis 9 month follow-up . Endpoints late luminal loss 9 month major adverse event include arterial thrombosis 1 , 9 12 month endpoint compare DCB BMS group .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Stable Angina Unstable angina single de novo coronary artery lesion single vessel &gt; 50 % diameter stenosis reference diameter &gt; 2.75mm Patients high risk bleed tolerate dual antiplatelet therapy &gt; 1 month inclusion criterion study list : Unexplained anemia Atrial fibrillation CHADSVASC &gt; equal 1 Patients await non cardiac surgery within year History massive hemorrhage require transfusion History upper GI bleeding Malignancy Poor compliance medication STEMI/NSTEMI within precede 72 hour Multivessel disease , chronic total occlusion , long lesion leave main disease heart failure ejection fraction &lt; 35 % and/or cardiogenic shock Previous history plan coronary artery bypass graft life expectancy le 1 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>